Portfolio News
- May 18, 2010 PregLem Announces Positive Phase III Results for Esmyatm as an Effective Treatment for Uterine Fibroids
- May 17, 2010 Anti-Pseudomonas Activity of KaloBios'/sanofi pasteur's KB001 May Prevent Serious Lung Infections and Limit Damaging Inflammation
- May 13, 2010 Amarin REPORTS Q1 2010 RESULTS - Positively updates guidance for ANCHOR and MARINE trials
- April 22, 2010 InteKrin Therapeutics Appoints Roman Skowronski, MD, PhD as Vice President of Clinical Development
- April 12, 2010 PregLem Licenses Additional Rights for Ulipristal Acetate from HRA Pharma
- April 06, 2010 Anthera Pharmaceuticals Announces Closing of Underwriters' Exercise of Over-Allotment Option in Connection With Its Initial Public Offering
- March 31, 2010 Orexigen(R) Therapeutics Submits Contrave(R) New Drug Application to FDA for the Treatment of Obesity
- March 29, 2010 Trius Announces Results from Phase 1 Clinical Trial Of Intravenous Torezolid Phosphate
- March 29, 2010 Multiple Myeloma Research Foundation (MMRF) Grants $1.0 Million to Intellikine to Advance Next-Generation Therapies for Multiple Myeloma
- March 24, 2010 Movetis Announces that Resolor® is Now Available in the UK
- March 08, 2010 - San Diego Business JournalOcera Tests Drug to Treat Little-Known Condition
- March 04, 2010 Anthera Pharmaceuticals Completes Initial Public Offering
- February 23, 2010 Intellikine Appoints William Rohn to Its Board of Directors
- February 23, 2010 Ocera Therapeutics Completes Phase 2B Enrollment in the ASTUTE Trial
- February 08, 2010 Anthera Pharmaceuticals Announces Agreement with the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
< More recent articles | Past articles >
Media Contact
Karen Kamel
Marketing Director
Sofinnova Ventures
karen@sofinnova.com
(424) 230-2672
